CLL1 modulator CAR-NK cell therapy (Hangzhou Qihan Biotech/Zhejiang University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameCLL1 modulator CAR-NK cell therapy (Hangzhou Qihan Biotech/Zhejiang University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cells stimulantsC-Type lectin domain family 12 member A modulators
TargetsC-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOtech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOtech Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A